Using Nanotechnology to Change Cancer Care
Maryland Technology Day
28 February 2013

The Promise of Cancer Nanomedicines
Deliver potent an6-‐cancer agents directly to the site of disease
 Reduced or no toxicity
 Improved efficacy
Treat cancer as a medical disease first
 Dose intravenously prior to surgery
 Limited biodistribu6on due to leaky tumor blood vessels
 Reduce tumor burden by tumor-‐targeted nanomedicines
 Reduce or eliminate sophis6cated surgical procedures
 Improve pa6ent outcome
Treat cancer as a chronic medical disease
 Treat periodically to destroy nascent tumor neovasculature
 Suppress metasta6c disease
2

Design of Aurimune (CYT-‐6091):
Water absorbed by
PEG-THIOL shields nanoparticle from immune detection
3

Safe, Targeted Delivery: Size MaGers
Too Large for Toxic Side Effects. Aurimune is small enough to safely travel through healthy blood vessels, but too large to pass through blood vessel walls into healthy 6ssues and organs, resul6ng in reduced toxicity.
Small Enough to Exit Tumor Vessels. All solid tumors are fueled by new, “ leaky ” blood vessels that have gaps in their walls. When Aurimune reaches these “ leaky ” vessels, the nanopar6cles are small enough to pass through these walls into their target, the tumor.
Due to its engineered nanometer size and targeted capabiliJes,
Aurimune is able to reduce toxicity and increase efficacy.
4

Clinical Grade Aurimune
Current produc6on capacity scaled 10-‐fold from Phase I to Phase II
 Process is robust, reproducible and cost effec6ve
 Solved manufacturing challenge for a nanomedicine
 3-‐year shelf life as a freeze dried product
5

Aurimune Phase I Trial: Clinical ObservaJons
Safe, systemic delivery. Delivered 1.2 mg of TNF with no dose limi6ng toxicity
 No Hypotension, the dose-‐limi6ng toxicity associated with TNF use in man
 No Serious Adverse Events that were unexpected and related treatment
Tumor targeted. Drug accumula6on at tumor sites
 Gold par6cles seen in tumors but few if any in healthy 6ssues
6

Electron Micrographs* of a PaJent ’ s Biopsies
Pa6ent diagnosed with inoperable breast cancer


Pa6ent had no prior treatment; samples taken 24h aYer treatment
Drug accumulated in tumor, not in healthy breast 6ssue
Healthy Breast
*Magnification = 20,000x 7
Tumor

Montefiore’s Commitment to Nanomedicine
8

The Pipeline: Leveraging PlaWorm’s Flexibility
PlaWorm allows for mulJple cancer treatments for mulJple cancer indicaJons
9

Blueprint of Gold-‐Based, Drug-‐Rescue Nanomedicine
PEG-‐THIOL
TNF:
A targeted VDA
AstraZeneca Proprietary
Drug
10

CytImmune Summary
Aurimune will transform current “ medieval ” approaches to cancer treatment
Aurimune plus chemotherapies aims to significantly improve responses rates
Aurimune is not another “ me too ” drug; it’s a quantum leap forward in cancer
Aurimune is the first-‐in-‐a-‐family of nanomedicines
CytImmune will create a pipeline of cancer nanomedicines
CytImmune’s technology will change the way we treat cancer
11